Signaturefd, LLC Dyne Therapeutics, Inc. Transaction History

Signaturefd, LLC

$5.4 Billion
Q2 2025

A detailed history of Signaturefd, LLC transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Signaturefd, LLC holds 290 shares of DYN stock, worth $3,236. This represents 0.0% of its overall portfolio holdings.

Number of Shares

290

Previous 731 60.33%

Holding current value

$3,236

Previous $7,000 71.43%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 16, 2025	SELL	$6.81 - $14.78 $3,003 - $6,517	-441 Reduced 60.33%	290 $2,000
Q1 2025 May 01, 2025	BUY	$10.46 - $25.46 $1,391 - $3,386	133 Added 22.24%	731 $7,000
Q4 2024 Feb 10, 2025	SELL	$23.56 - $35.55 $2,332 - $3,519	-99 Reduced 14.2%	598 $14,000
Q3 2024 Oct 21, 2024	BUY	$31.94 - $47.04 $1,852 - $2,728	58 Added 9.08%	697 $25,000
Q2 2024 Jul 29, 2024	BUY	$23.65 - $35.63 $969 - $1,460	41 Added 6.86%	639 $22,000
Q1 2024 May 03, 2024	BUY	$13.06 - $29.18 $248 - $554	19 Added 3.28%	598 $16,000
Q4 2023 Jan 31, 2024	BUY	$6.62 - $13.64 $3,098 - $6,383	468 Added 421.62%	579 $7,000
Q3 2023 Nov 03, 2023	SELL	$8.6 - $12.18 $885 - $1,254	-103 Reduced 48.13%	111 $0
Q2 2023 Aug 01, 2023	BUY	$8.53 - $14.28 $196 - $328	23 Added 12.04%	214 $2,000
Q3 2022 Nov 08, 2022	BUY	$7.2 - $15.17 $1,375 - $2,897	191 New	191 $2,000
Q2 2022 Aug 10, 2022	SELL	$4.36 - $10.5 $309 - $745	-71 Closed	0 $0
Q1 2022 May 02, 2022	BUY	$6.52 - $12.27 $462 - $871	71 New	71 $1,000
Q4 2021 Jan 25, 2022	SELL	$11.89 - $16.07 $582 - $787	-49 Closed	0 $0
Q3 2021 Oct 28, 2021	BUY	$15.6 - $21.46 $764 - $1,051	49 New	49 $1,000

Others Institutions Holding DYN

# of Institutions

217

Shares Held

116M

Call Options Held

322K

Put Options Held

66.2K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $578M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Signaturefd, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Signaturefd, LLC with notifications on news.

Account